Research ExplorerPublicationsBaseline and On-Treatment Markers Determining Prognosis of F...

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer

Standard

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. / Quidde, Julia; Denne, Laura; Kutscheidt, Andreas; Kindler, Manfred; Kirsch, Andreas; Kripp, Melanie; Petersen, Volker; Schulze, Matthias; Seraphin, Jörg; Tummes, Dirk; Arnold, Dirk; Stein, Alexander.

In: ONCOL RES TREAT, Vol. 40, No. 1-2, 2017, p. 21-26.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Quidde, J, Denne, L, Kutscheidt, A, Kindler, M, Kirsch, A, Kripp, M, Petersen, V, Schulze, M, Seraphin, J, Tummes, D, Arnold, D & Stein, A 2017, 'Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer', ONCOL RES TREAT, vol. 40, no. 1-2, pp. 21-26. https://doi.org/10.1159/000454774

APA

Quidde, J., Denne, L., Kutscheidt, A., Kindler, M., Kirsch, A., Kripp, M., Petersen, V., Schulze, M., Seraphin, J., Tummes, D., Arnold, D., & Stein, A. (2017). Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. ONCOL RES TREAT, 40(1-2), 21-26. https://doi.org/10.1159/000454774

Vancouver

Quidde J, Denne L, Kutscheidt A, Kindler M, Kirsch A, Kripp M et al. Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. ONCOL RES TREAT. 2017;40(1-2):21-26. https://doi.org/10.1159/000454774

Bibtex

@article{4a6fcb46926c41c3ac336723dfff3c9c,
title = "Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer",
abstract = "BACKGROUND: In metastatic colorectal cancer, no upfront or on-treatment markers are available to determine the prognosis or efficacy for chemotherapy in combination with bevacizumab.PATIENTS AND METHODS: The current analysis was performed to evaluate the prognostic value of disease and patient characteristics (age, number of metastatic sites, stage of primary tumor, performance status, carcinoembryonic antigen (CEA)) and on-treatment changes of CEA (response after 8-12 weeks of treatment and specific patterns of CEA kinetics) in patients from an observational cohort study of chemotherapy with bevacizumab.RESULTS: Baseline factors were available from 1,438 patients. Patients with baseline CEA levels > 20 ng/ml, more than 1 metastatic site, and age > 75 years showed significantly lower progression-free (PFS) and overall survival in multivariate analysis. A CEA response of > 30% during treatment was associated with increased PFS. In addition, the pattern of CEA kinetics predicts survival and response to treatment.CONCLUSION: In summary, baseline CEA, number of metastatic sites, and age are strong independent prognostic factors for survival. By monitoring CEA, clear patterns with distinct prognostic value can be determined. CEA kinetics and/or response after 8-12 weeks might be a useful and simple tool to stratify the post-induction treatment approach based on individual prognosis in the future.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Biomarkers, Carcinoembryonic Antigen, Cohort Studies, Colorectal Neoplasms, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Karnofsky Performance Status, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Time Factors, Journal Article, Observational Study",
author = "Julia Quidde and Laura Denne and Andreas Kutscheidt and Manfred Kindler and Andreas Kirsch and Melanie Kripp and Volker Petersen and Matthias Schulze and J{\"o}rg Seraphin and Dirk Tummes and Dirk Arnold and Alexander Stein",
note = "{\textcopyright} 2017 S. Karger GmbH, Freiburg.",
year = "2017",
doi = "10.1159/000454774",
language = "English",
volume = "40",
pages = "21--26",
journal = "ONCOL RES TREAT",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "1-2",

}

RIS

TY - JOUR

T1 - Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer

AU - Quidde, Julia

AU - Denne, Laura

AU - Kutscheidt, Andreas

AU - Kindler, Manfred

AU - Kirsch, Andreas

AU - Kripp, Melanie

AU - Petersen, Volker

AU - Schulze, Matthias

AU - Seraphin, Jörg

AU - Tummes, Dirk

AU - Arnold, Dirk

AU - Stein, Alexander

N1 - © 2017 S. Karger GmbH, Freiburg.

PY - 2017

Y1 - 2017

N2 - BACKGROUND: In metastatic colorectal cancer, no upfront or on-treatment markers are available to determine the prognosis or efficacy for chemotherapy in combination with bevacizumab.PATIENTS AND METHODS: The current analysis was performed to evaluate the prognostic value of disease and patient characteristics (age, number of metastatic sites, stage of primary tumor, performance status, carcinoembryonic antigen (CEA)) and on-treatment changes of CEA (response after 8-12 weeks of treatment and specific patterns of CEA kinetics) in patients from an observational cohort study of chemotherapy with bevacizumab.RESULTS: Baseline factors were available from 1,438 patients. Patients with baseline CEA levels > 20 ng/ml, more than 1 metastatic site, and age > 75 years showed significantly lower progression-free (PFS) and overall survival in multivariate analysis. A CEA response of > 30% during treatment was associated with increased PFS. In addition, the pattern of CEA kinetics predicts survival and response to treatment.CONCLUSION: In summary, baseline CEA, number of metastatic sites, and age are strong independent prognostic factors for survival. By monitoring CEA, clear patterns with distinct prognostic value can be determined. CEA kinetics and/or response after 8-12 weeks might be a useful and simple tool to stratify the post-induction treatment approach based on individual prognosis in the future.

AB - BACKGROUND: In metastatic colorectal cancer, no upfront or on-treatment markers are available to determine the prognosis or efficacy for chemotherapy in combination with bevacizumab.PATIENTS AND METHODS: The current analysis was performed to evaluate the prognostic value of disease and patient characteristics (age, number of metastatic sites, stage of primary tumor, performance status, carcinoembryonic antigen (CEA)) and on-treatment changes of CEA (response after 8-12 weeks of treatment and specific patterns of CEA kinetics) in patients from an observational cohort study of chemotherapy with bevacizumab.RESULTS: Baseline factors were available from 1,438 patients. Patients with baseline CEA levels > 20 ng/ml, more than 1 metastatic site, and age > 75 years showed significantly lower progression-free (PFS) and overall survival in multivariate analysis. A CEA response of > 30% during treatment was associated with increased PFS. In addition, the pattern of CEA kinetics predicts survival and response to treatment.CONCLUSION: In summary, baseline CEA, number of metastatic sites, and age are strong independent prognostic factors for survival. By monitoring CEA, clear patterns with distinct prognostic value can be determined. CEA kinetics and/or response after 8-12 weeks might be a useful and simple tool to stratify the post-induction treatment approach based on individual prognosis in the future.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bevacizumab

KW - Biomarkers

KW - Carcinoembryonic Antigen

KW - Cohort Studies

KW - Colorectal Neoplasms

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Karnofsky Performance Status

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Neoplasm Metastasis

KW - Neoplasm Staging

KW - Prognosis

KW - Time Factors

KW - Journal Article

KW - Observational Study

U2 - 10.1159/000454774

DO - 10.1159/000454774

M3 - SCORING: Journal article

C2 - 28192780

VL - 40

SP - 21

EP - 26

JO - ONCOL RES TREAT

JF - ONCOL RES TREAT

SN - 2296-5270

IS - 1-2

ER -